Cargando…
292. Ceftolozane/Tazobactam for Treatment of Osteomyelitis due to Multi-Drug-Resistant Pseudomonas aeruginosa
BACKGROUND: Ceftolozane/tazobactam (C/T) has potent activity against Pseudomonas aeruginosa (PA). Clinical data describing the use of C/T for PA osteomyelitis are limited. Our purpose is to describe clinical and microbiologic outcomes of adult patients treated with C/T for multidrug-resistant (MDR-P...
Autores principales: | Gerlach, Anthony, Bazan, Jose |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253306/ http://dx.doi.org/10.1093/ofid/ofy210.303 |
Ejemplares similares
-
Ceftolozane-tazobactam for the Treatment of Multi Drug-resistant Pseudomonas aeruginosa (MDRPA) Infections
por: Molnar, Esther, et al.
Publicado: (2017) -
2286. Evaluating the Impact of Ceftolozane/Tazobactam on Clinical Outcomes in Patients with Multi-Drug-resistant Pseudomonas aeruginosa Pneumonia
por: Mills, Matthew, et al.
Publicado: (2019) -
1597. Ceftolozane-Tazobactam and Meropenem Synergy Testing Against Multi-Drug and Extensively-Drug Resistant Pseudomonas aeruginosa
por: Chua, Mary Francine P, et al.
Publicado: (2020) -
Ceftolozane-Tazobactam Resistance in Multidrug-Resistant Pseudomonas aeruginosa Isolates Not Associated with AmpC Activity
por: Tran, Truc T, et al.
Publicado: (2017) -
2291. Evaluation of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Patients Receiving Ceftolozane/tazobactam
por: Bodo, Emily C, et al.
Publicado: (2019)